• Home
  •  / Northwest Biotherapeutics

Northwest Biotherapeutics

OverviewSuggest Edit

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

TypePublic
Founded1998
HQBethesda, MD, USMap
Websitenwbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)17(+22%)
Revenue (FY, 2019)$2.4 M(+485%)
Share Price (Jan 2021)$1.4 (+5%)
Cybersecurity ratingAMore

Key People/Management at Northwest Biotherapeutics

Les Goldman

Les Goldman

Senior Vice President, Business Development
Marnix L. Bosch

Marnix L. Bosch

Chief Technical Officer
Alton L. Boynton

Alton L. Boynton

Chief Scientific Officer
Show more

Northwest Biotherapeutics Office Locations

Northwest Biotherapeutics has an office in Bethesda
Bethesda, MD, US (HQ)
4800 Montgomery Ln
Show all (1)

Northwest Biotherapeutics Financials and Metrics

Northwest Biotherapeutics Revenue

Northwest Biotherapeutics's revenue was reported to be $2.41 m in FY, 2019
USD

Revenue (Q2, 2020)

2.0k

Net income (Q2, 2020)

(58.0m)

EBIT (Q2, 2020)

(7.4m)

Market capitalization (19-Jan-2021)

1.2b

Closing stock price (19-Jan-2021)

1.4

Cash (30-Sept-2020)

9.3m

EV

1.2b
Northwest Biotherapeutics's current market capitalization is $1.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.0k772.0k809.0k1.5m1.7m623.0k336.0k412.0k2.4m

Cost of goods sold

Gross profit

10.0k772.0k809.0k

Gross profit Margin, %

100%100%100%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.0k330.0k120.0k137.0k400.0k582.0k194.0k391.0k291.0k236.0k157.0k159.0k68.0k88.0k148.0k132.0k278.0k453.0k339.0k581.0k593.0k570.0k2.0k

Cost of goods sold

Gross profit

10.0k330.0k120.0k137.0k

Gross profit Margin, %

100%100%100%100%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.0k7.3m18.5m13.4m21.8m6.2m117.0k22.2m372.0k

Prepaid Expenses

94.0k112.0k147.0k387.0k1.4m1.0m1.3m1.6m2.8m

Current Assets

118.0k7.5m18.6m14.6m24.1m7.9m1.4m23.8m3.2m

PP&E

78.0k95.0k83.0k40.0m46.2m315.0k169.0k108.0k281.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

6.7m1.6m37.0k430.0k111.0k373.0k2.0m2.9m12.2m8.9m1.4m3.2m19.2m5.4m11.7m2.1m802.0k1.8m22.0k1.1m198.0k1.6m248.0k16.3m6.7m2.0m764.0k6.0m9.3m

Accounts Receivable

195.0k

Prepaid Expenses

69.0k170.0k79.0k260.0k186.0k39.0k363.0k138.0k147.0k177.0k167.0k666.0k978.0k950.0k1.1m1.5m785.0k923.0k797.0k1.1m931.0k838.0k870.0k2.3m2.2m2.6m2.8m2.3m2.9m

Current Assets

6.8m1.8m116.0k885.0k297.0k412.0k2.3m7.5m12.4m12.4m1.6m4.7m21.2m7.1m13.5m4.5m2.3m3.2m819.0k2.1m1.1m2.4m1.1m18.6m8.9m4.6m3.6m8.2m12.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(32.8m)(67.3m)(65.8m)(135.6m)(114.7m)(80.2m)(73.1m)(35.8m)(20.3m)

Depreciation and Amortization

10.0k14.0k11.0k11.0k56.0k189.0k439.0k1.3m21.0k

Accounts Payable

1.4m577.0k766.0k5.0m3.9m1.0m501.0k(436.0k)30.0k

Cash From Operating Activities

(14.7m)(22.8m)(37.8m)(54.6m)(78.6m)(55.7m)(36.5m)(34.6m)(31.9m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(20.7m)(20.3m)(10.2m)(20.3m)(36.8m)(14.4m)(26.0m)(48.9m)(46.0m)(71.9m)(92.9m)(46.4m)(113.3m)(90.7m)(6.1m)(20.3m)(49.5m)(12.6m)(22.9m)(46.1m)(21.5m)(42.7m)(30.1m)(20.9m)(20.7m)(27.0m)2.7m(55.2m)(249.5m)

Depreciation and Amortization

4.0k6.0k2.0k4.0k10.0k3.0k6.0k9.0k3.0k6.0k352.0k3.0k15.0k44.0k13.0k80.0k135.0k56.0k100.0k141.0k365.0k722.0k1.1m2.0k8.0k16.0k14.0k16.0k33.0k

Accounts Payable

680.0k1.1m2.0m5.4m10.5m299.0k1.0m1.1m277.0k1.4m3.7m(378.0k)2.2m7.1m(3.1m)628.0k1.7m514.0k3.2m4.4m(628.0k)857.0k4.5m(65.0k)(742.0k)62.0k1.2m2.1m986.0k

Cash From Operating Activities

(5.0m)(10.2m)(3.5m)(8.4m)(14.5m)(7.1m)(15.3m)(23.2m)(10.6m)(27.5m)(36.0m)(17.6m)(44.7m)(56.5m)(17.6m)(31.8m)(41.6m)(12.3m)(16.0m)(21.7m)(4.8m)(16.4m)(20.4m)(9.8m)(19.4m)(25.9m)(7.5m)(13.9m)(21.9m)
show all
USDQ2, 2011

Financial Leverage

-0.2 x
Show all financial metrics

Northwest Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about our premium products
SecurityScorecard logo

Northwest Biotherapeutics Online and Social Media Presence

Northwest Biotherapeutics's Trends

Embed Graph

Northwest Biotherapeutics Company Culture

  • CEO Rating

    F

    50/100

  • Compensation

    F

    10/100

Learn more on Comparably

Northwest Biotherapeutics News and Updates

October 05, 2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

BETHESDA, Md., Oct. 5, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been...
July 24, 2020

Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases

BETHESDA, Md., July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's...
January 18, 2019

Product Overview and Scope of Worldwide Castration Resistant Prostate Cancer Treatment Market forecast 2025 | TOP Key Players - Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceu

Summary: A new market study, titled “Discover Global Castration Resistant Prostate Cancer Treatment Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

Northwest Biotherapeutics Blogs

September 01, 2020

Northwest Biotherapeutics Acquires Flaskworks: Breakthrough Automation Technology For Cell Therapy Products To Enable Scale-Up of Production Volumes and Reduction of Production Costs

BETHESDA, Md., September 1, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system t... Th…
August 27, 2020

NW Bio Accelerating Sawston Plant Phase I Buildout: Construction Crews Working Double Shifts To Accelerate Completion Despite COVID Effects

BETHESDA, Md., August 27, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing preparations and planning as ... Th…
August 21, 2020

Northwest Biotherapeutics Announces $5 Million Financing: Non-Dilutive Debt; No Amortization For 7 Months; Maturity of 21 Months

BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L fo... Th…
August 19, 2020

NW Bio Announces Completion of Further Data Gathering For Phase III Trial

BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L fo... Th…
August 11, 2020

Northwest Biotherapeutics Announces $8 Million Financing: Financing On Favorable Terms; Further Broadening of Warrant Lock-Up

BETHESDA, Md., August 11, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million.  The ... Th…
July 24, 2020

Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites’ Databases

BETHESDA, Md., July 24, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company’s Phase 3 trial of DC... Th…
Show more

 Northwest Biotherapeutics Frequently Asked Questions

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1998.

  • Who are Northwest Biotherapeutics key executives?

    Northwest Biotherapeutics's key executives are Les Goldman, Marnix L. Bosch and Alton L. Boynton.

  • How many employees does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 17 employees.

  • What is Northwest Biotherapeutics revenue?

    Latest Northwest Biotherapeutics annual revenue is $2.4 m.

  • What is Northwest Biotherapeutics revenue per employee?

    Latest Northwest Biotherapeutics revenue per employee is $141.8 k.

  • Who are Northwest Biotherapeutics competitors?

    Competitors of Northwest Biotherapeutics include OncoResponse, Karyopharm Therapeutics and LiPlasome Pharma.

  • Where is Northwest Biotherapeutics headquarters?

    Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.

  • Where are Northwest Biotherapeutics offices?

    Northwest Biotherapeutics has an office in Bethesda.

  • How many offices does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 1 office.